EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release [by providing a written notice of revocation to the Company’s Chief Executive Officer]; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, i
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LOAN AND SECURITY AGREEMENT, dated as of March 30, 2011 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is among GENERAL ELECTRIC CAPITAL CORPORATION (“GECC”), in its capacity as agent for Lenders (as defined below) (together with its successors and assigns in such capacity, “Agent”), the financial institutions who are or hereafter become parties to this Agreement as lenders (together with GECC, collectively the “Lenders”, and each individually, a “Lender”), Syndax Pharmaceuticals, Inc., a Delaware corporation (“Borrower”), and the other entities or persons, if any, who are or hereafter become parties to this Agreement as guarantors (each a “Guarantor” and collectively, the “Guarantors”, and together with Borrower, each a “Loan Party” and collectively, “Loan Parties”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of January 18, 2013, is entered into by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of October 9, 2012, is entered into by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of March 8, 2013, is entered into by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of February 20, 2013, is entered into by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of November 19, 2012, is entered into by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of June 28, 2012, by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of March 1, 2013, is entered into by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
CONSENT AND AMENDMENT AGREEMENTConsent and Amendment Agreement • December 23rd, 2013 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Consent and Amendment Agreement (this “Agreement”), dated as of December 20, 2011, by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors and permitted assigns, “Agent”).
